Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 10/20 | 0.60 |
| ▸ | TAS1R1 | Q7RTX1 | 10/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14486846 | 0.83 | TAS1R3 (0.57) | TAS1R3TAS1R1MAPK1ALDH1A1KDM4E | |
| SCHEMBL14798404 | 0.79 | TAS1R3 (0.54) | TAS1R3TAS1R1MAPK1ALDH1A1KDM4E | |
| SCHEMBL5424180 | 0.77 | TAS1R3 (0.61) | TAS1R3TAS1R1ALDH1A1HPGDKDM4E | |
| SCHEMBL13293378 | 0.76 | TAS1R3 (0.52) | TAS1R3TAS1R1MAPK1ALDH1A1KDM4E | |
| SCHEMBL4205980 | 0.75 | TAS1R3 (1.00) | TAS1R3TAS1R1ALDH1A1KDM4EKMT2A | |
| SCHEMBL4205978 | 0.75 | TAS1R3 (1.00) | TAS1R3TAS1R1ALDH1A1KDM4EKMT2A | |
| SCHEMBL8985829 | 0.75 | CA12 (0.58) | TAS1R3TAS1R1ALDH1A1HPGDKDM4E | |
| SCHEMBL1739421 | 0.75 | ALDH1A1 (0.66) | TAS1R3TAS1R1MAPK1ALDH1A1KDM4E | |
| SCHEMBL5782189 | 0.74 | KMT2A (0.54) | TAS1R3TAS1R1ALDH1A1HPGDMEN1 | |
| SCHEMBL5784044 | 0.74 | SMN1; SMN2 (0.55) | ALDH1A1HPGDMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321787-B2 | Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring | SANOFI (FR) | 2016-04-26 | — | — | US | disclosed |
| US-9321787-B2 | Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring | SANOFI (FR) | 2016-04-26 | — | — | US | disclosed |
| EP-2729471-B1 | CARBOXYLIC ACID DERIVATIVES WITH AN OXAZOLO[5,4-D]PYRIMIDINE RING | SANOFI SA (FR) | 2015-05-06 | — | — | EP | disclosed |
| EP-2729471-B1 | CARBOXYLIC ACID DERIVATIVES WITH AN OXAZOLO[5,4-D]PYRIMIDINE RING | SANOFI SA (FR) | 2015-05-06 | — | — | EP | disclosed |
| US-8846691-B2 | Heterocyclic carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8748436-B2 | Carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| EP-2729471-A1 | CARBOXYLIC ACID DERIVATIVES HAVING AN OXAZOLO[5,4-D]PYRIDINE RING | SANOFI (FR) | 2014-05-14 | — | — | EP | disclosed |
| EP-2523958-B1 | CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI SA (FR) | 2013-12-25 | — | — | EP | disclosed |
| EP-2523959-B1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI SA (FR) | 2013-11-27 | — | — | EP | disclosed |
| US-20130158051-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2013-06-20 | — | — | US | disclosed |
| US-20130079357-A1 | CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2013-03-28 | — | — | US | disclosed |
| US-20130023544-A1 | CARBOXYLIC ACID DERIVATIVES HAVING AN OXAZOLO[5,4-d]PYRIMIDINE RING | SANOFI (FR) | 2013-01-24 | — | — | US | disclosed |
| US-20130023544-A1 | CARBOXYLIC ACID DERIVATIVES HAVING AN OXAZOLO[5,4-d]PYRIMIDINE RING | SANOFI (FR) | 2013-01-24 | — | — | US | disclosed |
| WO-2013004827-A1 | CARBOXYLIC ACID DERIVATIVES HAVING AN OXAZOLO[5,4-D]PYRIDINE RING | SANOFI (FR) | 2013-01-10 | — | — | WO | disclosed |
| EP-2523958-A1 | CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2012-11-21 | — | — | EP | disclosed |
| EP-2523959-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011086077-A1 | CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011086078-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079357-A1 | CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | DPYD, OXGR1, ALDH1A1 | TAS1R3 2462/4885TAS1R1 1841/4885MAPK1 1499/4885 |
| US-20130158051-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | OXGR1, DPYD, FGF2 | TAS1R3 2452/4885TAS1R1 1804/4885MAPK1 1408/4885 |
| US-20130023544-A1 | CARBOXYLIC ACID DERIVATIVES HAVING AN OXAZOLO[5,4-d]PYRIMIDINE RING | OXGR1, CXCR1, DPYD | TAS1R3 2002/4885TAS1R1 1760/4885MAPK1 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.